Analyst Ratings for [ARRY] Array BioPharma Inc.

3/7/25	Upgrades	Neutral Buy	X
ARRY Array Tech Guggenheim
$10
2/28/25	Downgrades	Buy Neutral	X
ARRY Array Tech Seaport Research Partners
2/28/25	Reiterated	Hold	X
ARRY Array Tech TD Cowen
$10 $7
2/6/25	Upgrades	Underperform Neutral	X
ARRY Array Tech Exane BNP Paribas
$9
1/10/25	Downgrades	Positive Neutral	X
ARRY Array Tech Susquehanna
$7
11/8/24	Reiterated	Hold	X
ARRY Array Tech TD Cowen
$11.50 $10
11/7/24	Downgrades	Buy Neutral	X
ARRY Array Tech BofA Securities
$11 $7
11/7/24	Downgrades	Buy Neutral	X
ARRY Array Tech Guggenheim
9/4/24	Resumed	Buy	X
ARRY Array Tech Jefferies
$11
8/9/24	Downgrades	Buy Neutral	X
ARRY Array Tech ROTH MKM
$20 $8
8/9/24	Reiterated	Hold	X
ARRY Array Tech TD Cowen
$16.50 $11.50
7/12/24	Upgrades	Neutral Buy	X
ARRY Array Tech Citigroup
$17 $14
6/28/24	Initiated	Positive	X
ARRY Array Tech Susquehanna
$14
5/10/24	Upgrades	Perform Outperform	X
ARRY Array Tech Oppenheimer
$20
4/2/24	Upgrades	Eq Weight Overweight	X
ARRY Array Tech Barclays
$15 $18
3/22/24	Initiated	Market Perform	X
ARRY Array Tech BMO Capital Markets
$16
3/5/24	Initiated	Sector Weight	X
ARRY Array Tech KeyBanc Capital Markets
2/28/24	Downgrades	Neutral Underperform	X
ARRY Array Tech Exane BNP Paribas
$12
2/28/24	Reiterated	Market Perform	X
ARRY Array Tech TD Cowen
$22.50 $16.50
1/22/24	Downgrades	Overweight Eq Weight	X
ARRY Array Tech Barclays
$22 $15
1/8/24	Downgrades	Overweight Eq Weight	X
ARRY Array Tech Wells Fargo
$22 $19
12/19/23	Downgrades	Overweight Neutral	X
ARRY Array Tech Piper Sandler
$26 $22
12/15/23	Initiated	Hold	X
ARRY Array Tech Jefferies
$18
11/21/23	Initiated	Neutral	X
ARRY Array Tech Mizuho
$19
10/20/23	Initiated	Neutral	X
ARRY Array Tech Exane BNP Paribas
$21
6/28/23	Initiated	Buy	X
ARRY Array Tech Janney
$37
5/18/23	Initiated	Buy	X
ARRY Array Tech Seaport Research Partners
$30
4/11/23	Initiated	Outperform	X
ARRY Array Tech Wolfe Research
$25
4/3/23	Resumed	Underweight	X
ARRY Array Tech Morgan Stanley
$16 $17
3/28/23	Upgrades	Hold Buy	X
ARRY Array Tech Truist
$26
3/10/23	Initiated	Neutral	X
ARRY Array Tech Citigroup
$24
3/2/23	Initiated	Sector Outperform	X
ARRY Array Tech Scotiabank
$26
12/23/22	Initiated	Overweight	X
ARRY Array Tech Cantor Fitzgerald
$26
12/6/22	Initiated	Overweight	X
ARRY Array Tech Wells Fargo
$28
9/19/22	Upgrades	Neutral Overweight	X
ARRY Array Tech Piper Sandler
$20 $28
8/18/22	Downgrades	Eq-Weight Underweight	X
ARRY Array Tech Morgan Stanley
$17 $15
8/5/22	Initiated	Overweight	X
ARRY Array Tech Barclays
$20
6/6/22	Upgrades	Neutral Buy	X
ARRY Array Tech ROTH Capital
5/23/22	Initiated	Outperform	X
ARRY Array Tech Northland Capital
$18
5/11/22	Downgrades	Buy Neutral	X
ARRY Array Tech ROTH Capital
$25 $7
5/2/22	Resumed	Hold	X
ARRY Array Tech Truist
$14
1/18/22	Resumed	Neutral	X
ARRY Array Tech Guggenheim
10/20/21	Downgrades	Buy Neutral	X
ARRY Array Tech Guggenheim
10/15/21	Initiated	Hold	X
ARRY Array Tech Truist
$23
7/20/21	Upgrades	Underweight Eq Weight	X
ARRY Array Tech Barclays
$15
7/14/21	Resumed	Outperform	X
ARRY Array Tech Credit Suisse
$31
5/13/21	Upgrades	Neutral Outperform	X
ARRY Array Tech Credit Suisse
$42 $31
5/12/21	Downgrades	Overweight Underweight	X
ARRY Array Tech Barclays
$32 $16
5/12/21	Reiterated	Market Perform	X
ARRY Array Tech Cowen
$45.50 $24
5/12/21	Downgrades	Overweight Neutral	X
ARRY Array Tech Piper Sandler
$53 $27
5/12/21	Downgrades	Buy Neutral	X
ARRY Array Tech ROTH Capital
$53 $25
4/22/21	Upgrades	Eq Weight Overweight	X
ARRY Array Tech Barclays
4/16/21	Upgrades	Neutral Buy	X
ARRY Array Tech UBS
$43
3/29/21	Upgrades	Underweight Eq-Weight	X
ARRY Array Tech Morgan Stanley
$30
3/10/21	Upgrades	Accumulate Buy	X
ARRY Array Tech Johnson Rice
$50
1/20/21	Initiated	Accumulate	X
ARRY Array Tech Johnson Rice
$57
1/8/21	Initiated	Overweight	X
ARRY Array Tech Piper Sandler
$60
1/17/19	Initiated	Outperform	X
ARRY Array Biopharma Leerink Partners
$28
12/13/18	Initiated	Neutral	X
ARRY Array Biopharma Goldman
$20
2/7/18	Reiterated	Buy	X
ARRY Array Biopharma Stifel
$20 $23

ARRY Array BioPharma Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.